The DOI matches its Crossref record.
Metal-based anticancer chemotherapeutic agents
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 53
- Rosenberg, 1965, Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode, Nature, 205, 698, 10.1038/205698a0 · DOI · Paper page
- Guo, 1999, Medicinal inorganic chemistry, Adv Inorg Chem, 49, 183, 10.1016/S0898-8838(08)60271-8 · DOI · Paper page
- Kelland, 2007, The resurgence of platinum-based cancer chemotherapy, Nat Rev Cancer, 7, 573, 10.1038/nrc2167 · DOI · Paper page
- Wang, 2013, Targeting and delivery of platinum-based anticancer drugs, Chem Soc Rev, 42, 202, 10.1039/C2CS35259A · DOI · Paper page
- Butler, 2013, Targeted delivery of platinum-based anticancer complexes, Curr Opin Chem Biol, 17, 175, 10.1016/j.cbpa.2013.01.004 · DOI · Paper page
- Barry, 2013, Exploration of the medical periodic table: towards new targets, Chem Commun (Camb), 49, 5106, 10.1039/c3cc41143e · DOI · Paper page
- Rosenberg, 1969, Platinum compounds: a new class of potent antitumour agents, Nature, 222, 385, 10.1038/222385a0 · DOI · Paper page
- Wheate, 2010, The status of platinum anticancer drugs in the clinic and in clinical trials, Dalton Trans, 39, 8113, 10.1039/c0dt00292e · DOI · Paper page
- Wexselblatt, 2012, What do we know about the reduction of Pt(IV) pro-drugs?, J Inorg Biochem, 117, 220, 10.1016/j.jinorgbio.2012.06.013 · DOI · Paper page
- Kozubik, 2005, High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro, Biochem Pharmacol, 69, 373, 10.1016/j.bcp.2004.09.005 · doi:10.1016/j.bcp.2004.09.005
- Wilson, 2011, Synthesis, characterization, and cytotoxicity of platinum(IV) carbamate complexes, Inorg Chem, 50, 3103, 10.1021/ic2000816 · DOI
- Medrano, 2013, Oxidation of anticancer Pt(II) complexes with monodentate phosphane ligands: towards stable but active Pt(IV) prodrugs, Chem Commun (Camb), 49, 4806, 10.1039/c3cc38416k · doi:10.1039/c3cc38416k
- Varbanov, 2012, Novel tetracarboxylatoplatinum(IV) complexes as carboplatin prodrugs, Dalton Trans, 41, 14404, 10.1039/C2DT31366A · doi:10.1039/c2dt31366a
- Ravera, 2012, Synthesis, characterization and antiproliferative activity on mesothelioma cell lines of bis(carboxylato)platinum(IV) complexes based on picoplatin, Dalton Trans, 41, 3313, 10.1039/c2dt11874b · doi:10.1039/c2dt11874b
- Pichler, 2013, Bulky N(,N)-(di)alkylethane-1,2-diamineplatinum(II) compounds as precursors for generating unsymmetrically substituted platinum(IV) complexes, Inorg Chem, 52, 8151, 10.1021/ic400816g · doi:10.1021/ic400816g
- Farrer, 2010, A potent trans-diimine platinum anticancer complex photoactivated by visible light, Angew Chem Int Ed, 49, 8905, 10.1002/anie.201003399 · doi:10.1002/anie.201003399
- Song, 2013, Synthesis and characterization of Pt(IV) fluorescein conjugates to investigate Pt(IV) intracellular transformations, Bioconjugate Chem, 24, 1733, 10.1021/bc400281a · DOI
- Aryal, 2010, Polymer cisplatin conjugate nanoparticles for acid-responsive drug delivery, ACS Nano, 4, 251, 10.1021/nn9014032 · DOI · Paper page
- Kolishetti, 2010, Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy, PNAS, 107, 17939, 10.1073/pnas.1011368107 · DOI · Paper page
- Xiao, 2012, A prodrug strategy to deliver cisplatin(IV) and paclitaxel in nanomicelles to improve efficacy and tolerance, Biomaterials, 33, 6507, 10.1016/j.biomaterials.2012.05.049 · DOI · Paper page
- Graf, 2012, αVβ3 integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug, ACS Nano, 6, 4530, 10.1021/nn301148e · DOI · Paper page
- Wedlock, 2013, NanoSIMS multi-element imaging reveals internalisation and nucleolar targeting for a highly-charged polynuclear platinum compound, Chem Commun (Camb), 49, 6944, 10.1039/c3cc42098a · doi:10.1039/c3cc42098a
- Manzotti, 2000, BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin, Clin Cancer Res, 6, 2626
- Zhao, 2006, A positively charged trinuclear 3N-chelated monofunctional platinum complex with high DNA affinity and potent cytotoxicity, Dalton Trans, 2617, 10.1039/b601739h · doi:10.1039/b601739h
- Wang, 2011, Noncovalent interactions between a trinuclear monofunctional platinum complex and human serum albumin, Inorg Chem, 50, 12661, 10.1021/ic201712e · doi:10.1021/ic201712e
- Olivova, 2011, Unique DNA binding mode of antitumor trinuclear tridentate platinum(II) compound, Mol Pharm, 8, 2368, 10.1021/mp200298g · DOI
- Zerzankova, 2010, Mechanistic insights into antitumor effects of new dinuclear cis Pt(II) complexes containing aromatic linkers, Biochem Pharmacol, 80, 344, 10.1016/j.bcp.2010.04.013 · doi:10.1016/j.bcp.2010.04.013
- Lin, 2011, Cellular and biomolecular responses of human ovarian cancer cells to cytostatic dinuclear platinum(II) complexes, Apoptosis, 16, 288, 10.1007/s10495-010-0562-0 · DOI
- Komeda, 2011, A tetrazolato-bridged dinuclear platinum(II) complex exhibits markedly high in vivo antitumor activity against pancreatic cancer, ChemMedChem, 6, 987, 10.1002/cmdc.201100141 · doi:10.1002/cmdc.201100141
- Komeda, 2013, Synthesis of antitumor azolato-bridged dinuclear platinum(II) complexes with in vivo antitumor efficacy and unique in vitro cytotoxicity profiles, Metallomics, 5, 461, 10.1039/c3mt00040k · doi:10.1039/c3mt00040k
- Brown, 2012, Combining aspects of the platinum anticancer drugs picoplatin and BBR3464 to synthesize a new family of sterically hindered dinuclear complexes; their synthesis, binding kinetics and cytotoxicity, Dalton Trans, 41, 11330, 10.1039/c2dt31313h · doi:10.1039/c2dt31313h
- Sava, 2011, Metal-based antitumour drugs in the post-genomic era: what comes next?, Dalton Trans, 40, 9069, 10.1039/c1dt10522a · DOI · Paper page
- Lakomska, 2013, Synthesis, characterization and antitumor properties of two highly cytotoxic ruthenium(III) complexes with bulky triazolopyrimidine ligands, Dalton Trans, 42, 6219, 10.1039/c2dt32216a · doi:10.1039/c2dt32216a
- Pierroz, 2012, Molecular and cellular characterization of the biological effects of ruthenium(II) complexes incorporating 2-pyridyl-2-pyrimidine-4-carboxylic acid, J Am Chem Soc, 134, 20376, 10.1021/ja307288s · DOI · Paper page
- Li, 2012, Ruthenium complexes containing bis-benzimidazole derivatives as a new class of apoptosis inducers, Dalton Trans, 41, 1138, 10.1039/C1DT11950H · doi:10.1039/c1dt11950h
- Qian, 2013, The induction of mitochondria-mediated apoptosis in cancer cells by ruthenium(II) asymmetric complexes, Metallomics, 5, 844, 10.1039/c3mt20270d · DOI
- Ang, 2011, Organometallic ruthenium-based antitumor compounds with novel modes of action, J Organomet Chem, 696, 989, 10.1016/j.jorganchem.2010.11.009 · DOI · Paper page
- Suss-Fink, 2010, Arene ruthenium complexes as anticancer agents, Dalton Trans, 39, 1673, 10.1039/B916860P · DOI
- Kilpin, 2013, Ruthenium(II) arene PTA (RAPTA) complexes: impact of enantiomerically pure chiral ligands, Dalton Trans, 42, 2008, 10.1039/C2DT32333H · doi:10.1039/c2dt32333h
- Khan, 2013, Arene ruthenium dichloro complexes containing isonicotinic ester ligands: synthesis, molecular structure and cytotoxicity, J Organomet Chem, 730, 49, 10.1016/j.jorganchem.2012.10.016 · doi:10.1016/j.jorganchem.2012.10.016
- Romero-Canelon, 2013, The contrasting activity of iodido versus chlorido ruthenium and osmium arene azo- and imino-pyridine anticancer complexes: control of cell selectivity, cross-resistance, p53 dependence, and apoptosis pathway, J Med Chem, 56, 1291, 10.1021/jm3017442 · DOI · Paper page
- Barry, 2012, Dicarba-closo-dodecarborane-containing half-sandwich complexes of ruthenium, osmium, rhodium and iridium: biological relevance and synthetic strategies, Chem Soc Rev, 41, 3264, 10.1039/c2cs15300a · DOI
- Ott, 2009, On the medicinal chemistry of gold complexes as anticancer drugs, Coord Chem Rev, 253, 1670, 10.1016/j.ccr.2009.02.019 · DOI · Paper page
- Bindoli, 2009, Thioredoxin reductase: a target for gold compounds acting as potential anticancer drugs, Coord Chem Rev, 253, 1692, 10.1016/j.ccr.2009.02.026 · DOI · Paper page
- Serratrice, 2012, Cytotoxic gold compounds: synthesis, biological characterization and investigation of their inhibition properties of the zinc finger protein PARP-1, Dalton Trans, 41, 3287, 10.1039/c2dt11913g · doi:10.1039/c2dt11913g
- Zou, 2013, Gold(III) complexes containing N-heterocyclic carbene ligands: thiol “switch-on” fluorescent probes and anti-cancer agents, Angew Chem Int Ed, 52, 2930, 10.1002/anie.201209787 · DOI · Paper page
- Ronconi, 2009, The Midas touch in cancer chemotherapy: from platinum- to gold-dithiocarbamato complexes, Dalton Trans, 10670, 10.1039/b913597a · doi:10.1039/b913597a
- Zhang, 2013, Deubiquitinases as potential anti-cancer targets for gold(iii) complexes, Chem Commun (Camb), 49, 5153, 10.1039/c3cc41766b · DOI
- Buettner, 2012, Bioinorganic chemistry of titanium, Chem Rev, 112, 1863, 10.1021/cr1002886 · DOI · Paper page
- Tshuva, 2009, Modern cytotoxic titanium(IV) complexes; insights on the enigmatic involvement of hydrolysis, Coord Chem Rev, 253, 2098, 10.1016/j.ccr.2008.11.015 · DOI
- Glasner, 2011, A marked synergistic effect in antitumor activity of salan titanium(IV) complexes bearing two differently substituted aromatic rings, J Am Chem Soc, 133, 16812, 10.1021/ja208219f · DOI
- Meker, 2012, High antitumor activity of highly resistant salan-titanium(IV) complexes in nanoparticles: an identified active species, Angew Chem Int Ed Engl, 51, 10515, 10.1002/anie.201205973 · doi:10.1002/anie.201205973
- Tzubery, 2011, Trans titanium(IV) complexes of salen ligands exhibit high antitumor activity, Inorg Chem, 50, 7946, 10.1021/ic201296h · DOI
Cited by
Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer
Mármol, I., Sánchez-de-Diego, C., Pradilla Dieste, A., Cerrada, E., & Rodriguez Yoldi, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010197 · Cited by 1,525
Zeng, L., Gupta, P., Chen, Y., Wang, E., Ji, L., Chao, H., & Chen, Z.-S. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00195a · Cited by 1,017
Stimuli-Responsive Therapeutic Metallodrugs
Wang, X., Wang, X., Jin, S., Muhammad, N., & Guo, Z. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00209 · Cited by 649
Self-citationHypoxia-targeted drug delivery
Sharma, A., Arambula, J. F., Koo, S., Kumar, R., Singh, H., Sessler, J. L., & Kim, J. S. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00304a · Cited by 542
Meier-Menches, S. M., Gerner, C., Berger, W., Hartinger, C. G., & Keppler, B. K. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00332c · Cited by 425
Metadata
- Authors
- Muhammad, N., & Guo, Z.
- Venue
- Current Opinion in Chemical Biology
- Publisher
- Elsevier BV
- Published
- 2014-04
- Volume
- 19
- Pages
- 144-153
- ISSN
- 1367-5931 (ISSN-L)
- OpenAlex
- W2090858808
- Cited by
- 515
- References
- 0
- FWCI
- 5.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- National Basic Research Program of China (2011CB935800)
- National Natural Science Foundation of China (21271100, 91213305, 10979019, 21131003, 21021062)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metal-based anticancer chemotherapeutic agents. https://app.cochat.ai/papers/10.1016/j.cbpa.2014.02.003
- The paper
- Muhammad, N., & Guo, Z. (2014). Metal-based anticancer chemotherapeutic agents. Current Opinion in Chemical Biology. https://doi.org/10.1016/j.cbpa.2014.02.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.